January 3rd, 2012
Bariatric Surgery Cuts Cardiovascular Deaths and Events
Larry Husten, PHD
Bariatric surgery results in significant reductions in cardiovascular deaths and events, according to a new study from Sweden published in JAMA. But one expert cautions that the results do not mean that obese patients without other weight-related complications should undergo surgery.
Analyzing data from more than 4000 obese patients enrolled in the ongoing Swedish Obese Subjects (SOS) study, Lars Sjöström and colleagues found that bariatric surgery was associated with a reduction in cardiovascular events and deaths after a median follow-up of 14.7 years. (The investigators had previously reported a reduction in total mortality in the surgery group.)
- CV deaths: 28 in the surgery group versus 49 in the control group (HR 0.47, CI 0.29- 0.76, p=0.002)
- MI or stroke: 199 versus 234, (HR 0.67, CI 0.54-0.83, p<0.001)
In a surprising finding, the investigators found no significant association between either weight at baseline or weight loss after surgery and cardiovascular events. The authors speculate this may have been due to the low statistical power of the study to detect an association or, alternatively, that the greatest benefit was derived from the initial modest weight loss caused by the surgery.
Taken with previous reports, the results, write the authors, “demonstrate that there are many benefits to bariatric surgery and that some of these benefits are independent of the degree of the surgically induced weight loss.”
In an accompanying editorial, Edward Livingston writes that “because the expected health benefits do not necessarily exceed the risks of weight loss operations, obese patients without other weight-related complications generally should not undergo bariatric surgery.” He suggests that the NIH convene a new expert panel “to rigorously assess the available evidence and provide updated recommendations for bariatric procedures for the treatment of obesity.”
Categories: Cardiac Surgery, General, Prevention
Tags: bariatric surgery, weight loss
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026The landscape of treatment options for venous thromboembolism was transformed by the arrival of direct oral anticoagulants. Large-scale trials showed that the direct oral anticoagulants apixaban and rivaroxaban were noninferior to vitamin K antagonists in terms of efficacy and had a better safety profile. However, for over a decade, a...
- Case 8-2026: A 57-Year-Old Woman with Chest Pain, Dyspnea, and Syncope March 12, 2026A 57-year-old woman was evaluated because of 2 days of chest pain and dyspnea. Ultrasonography showed a pericardial effusion with diastolic inversion of the right ventricle. A diagnosis was made.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism March 12, 2026In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
- Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome March 5, 2026A CD19-targeted therapy induced remission in a woman with refractory immune thrombocytopenia and antiphospholipid syndrome by stabilizing platelet counts, eliminating pathogenic antibodies, and enabling safer long-term anticoagulation.
- Assessing Nonculprit Coronary-Artery Lesions in STEMI March 5, 2026Multivessel coronary artery disease is seen on invasive coronary angiography in approximately 50% of patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Previous trials have shown that in patients with hemodynamically stable disease, revascularization with percutaneous coronary intervention (PCI) of a nonculprit coronary lesion results in better outcomes than...
- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
